Thursday, November 5, 2026
BTC $75,918 ▼ 5.53%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
BTC$75,918down−5.53%ETH$2,252down−7.17%SOL$89.65down−6.39%XRP$1.24down−5.42%LINK$10.67down−7.39%ADA$0.182down−7.55%S&P 5007,411down−3.61%Nasdaq24,511down−4.76%Dow51,855down−2.81%RUT2,747down−3.85%TNX4.85%down−0.96%TYX5.26%down−0.45%FVX4.62%down−1.43%IRX4.00%down−0.62%VIX24.52up+47.62%GOLD$4,126.80up+1.32%SILVER$52.60up+0.60%OIL$90.50up+2.70%DXY101.44down−0.12%NVDA$184.49down−7.81%AAPL$344.09down−1.55%TSLA$341.69down−11.29%META$605.60down−3.87%MSFT$540.42down−2.77%AMZN$261.58down−1.67%GOOGL$285.47down−1.20%Fear & Greed50 — NeutralBTC$75,918down−5.53%ETH$2,252down−7.17%SOL$89.65down−6.39%XRP$1.24down−5.42%LINK$10.67down−7.39%ADA$0.182down−7.55%S&P 5007,411down−3.61%Nasdaq24,511down−4.76%Dow51,855down−2.81%RUT2,747down−3.85%TNX4.85%down−0.96%TYX5.26%down−0.45%FVX4.62%down−1.43%IRX4.00%down−0.62%VIX24.52up+47.62%GOLD$4,126.80up+1.32%SILVER$52.60up+0.60%OIL$90.50up+2.70%DXY101.44down−0.12%NVDA$184.49down−7.81%AAPL$344.09down−1.55%TSLA$341.69down−11.29%META$605.60down−3.87%MSFT$540.42down−2.77%AMZN$261.58down−1.67%GOOGL$285.47down−1.20%Fear & Greed50 — Neutral
Tag

argx

1 article

Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
U.S. Equities40d ago
Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
The biotech reported 60% year-over-year revenue growth in Q2 2026 on gMG and CIDP therapies, with Wall Street's consensus target at $1,180.25.